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Introduction:  PROP1  (Prophet  of POUF1)  mutations  are  the  most  frequent  genetic  cause  of  combined
pituitary  hormone  deﬁciency,  a condition  associated  with  a  deﬁciency  or  inadequate  production  of  hor-
mones of  the  anterior  pituitary.  The  PROP1  gene  encodes  a  transcription  factor  involved  in the  ontogeny,
differentiation  and  function  of somatotrophs,  lactotrophs  and  thyrotrophs.  These  mutations  are  charac-
terized  by  a remarkable  clinical  variability,  including  time  of onset  of  hormonal  deﬁciencies,  hypophyseal
dimensions  and  secretion  of  cortisol.
Case  report:  We  describe  a family  of consanguineous  parents  (second-degree  cousins),  composed  of  7
siblings,  4  with  combined  pituitary  hormone  deﬁciency.  Two  brothers,  41  and  45  years  of age,  had  an
initial  diagnosis  of dwarﬁsm  at ages  9 and  12  respectively.  Subsequently,  TSH,  FSH/LH  and  prolactin
deﬁciency  was detected  in  both. The  latter  was  also  diagnosed  with  cortisol  deﬁciency.  The  two  sisters,
aged  46  and  50-years-old,  were  diagnosed  with  combined  pituitary  hormone  deﬁciency,  namely  of  GH,
TSH,  FSH/LH,  prolactin  and  ACTH,  since  the ages  of  15 and  9,  respectively.  There  was  no  previous  family
history of  combined  pituitary  hormone  deﬁciency.  The  genetic  study  was performed  in  the  4 brothers,
detecting  a  homozygous  mutation  in the PROP1  gene  (c.301–302delAG).
Conclusion:  This case  reﬂects  the  variability  of clinical  expression  and  the  progressive  functional  impair-
ment,  including  pituitary  secretion  of ACTH,  in  patients  with  PROP1  gene  mutations.
©  2015  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier
España,  S.L.U.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Panhipopituitarismo  familiar  por  mutac¸ ão  do  gene  PROP1:  4  de  7  irmãos
afectados
alavras-chave:
ROP1
utac¸ ão
nsuﬁciência hormonal combinada
r  e  s  u  m  o
Introduc¸ ão:  As mutac¸ ões  no  gene  PROP1  (Prophet  of  POUF1)  são  a causa  genética  mais  frequente  de
insuﬁciência  hormonal  combinada,  uma  condic¸ ão associada  à  deﬁciência  ou  produc¸ ão inadequada  de
hormonas  da  hipóﬁse  anterior.  O gene  PROP1  codiﬁca  um  factor  de  transcric¸ ão envolvido  na  ontogê-
nese,  diferenciac¸ ão e func¸ ão dos  somatotrófos,  lactotrófos,  e tireotrófos.  Estas  mutac¸ ões caracterizam-se
por  uma  notável  variabilidade  clínica,  incluindo  o  início  do aparecimento  das  deﬁciências  hormonais,
dimensões  hipoﬁsárias  e secrec¸ ão  de  cortisol.
Caso clínico:  Família  de  pais  consanguíneos  (primos  em  segundo  grau),  composta  por  7  irmãos,  4  com  o
diagnóstico  de  insuﬁciência  hormonal  combinada,  seguidos  em  consulta  de Endocrinologia.  Dois  irmãos
do  sexo  masculino,  41  e 45  anos,  com  diagnóstico  inicial  de  nanismo  aos  9 e 12 anos  de  idade,  respetiva-
mente,  tendo sido  detetada  posteriormente  deﬁciência  de  TSH, FSH/LH  e prolactina,  em  ambos  e também
de  cortisol  no último.  As 2  irmãs,  de  46  e 50 anos  de  idade,  com  insuﬁciência  hormonal  combinada  por  deﬁ-
ciência  de  GH,  TSH,  FSH/LH,  prolactina  e  ACTH,  conﬁrmada  aos  15  e aos  9 anos  de  idade,  respetivamente.
Sem  história  familiar  prévia  de  insuﬁciência  hormonal  combinada.  Foi  efectuado  o estudo  genético,  tendo
sido possível  detectar  nos  4 irmãos  uma  mutac¸ ão  homozigótica  no gene  PROP1  (c.301–302delAG).
∗ Corresponding author.
E-mail address: evalau.med@gmail.com (E. Lau).
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Conclusão:  Esta  família  demonstra  a  variabilidade  da  expressão  clínica  dos portadores  de  mutac¸ ões  do
gene  PROP1  e a progressiva  alterac¸ ão funcional  hipoﬁsária,  nomeadamente  da secrec¸ ão  de ACTH.
© 2015 Sociedade  Portuguesa  de Endocrinologia,  Diabetes  e Metabolismo.  Publicado  por  Elsevier
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ntroduction
The anterior pituitary development during the embryonic
eriod is dependent on sequential and critical processes, from
nduction of Rathke’s pouch to pituitary organogenesis and cell
ine proliferation, speciﬁcation and differentiation. Deregulation of
hese steps can cause pituitary hypoplasia or dysfunction. Molec-
lar analysis has allowed the identiﬁcation of multiple genes
nvolved in the coordination of this differentiation.1 POUF1 gene
ncodes a transcriptional factor expressed during the differentia-
ion of the anterior pituitary gland, which is responsible for the
dequate production of growth hormone (GH), prolactin (PRL) and
hyroid-stimulating hormone (TSH). A second transcription factor
nvolved in pituitary development is the gene Prophet of POUF1
PROP1).2
Mutations in PROP1 gene are the most frequent genetic cause
f combined pituitary hormone deﬁciency, a condition associated
ith a deﬁciency or inadequate production of hormones of the
nterior pituitary.3 Prop1 gene (Prophet of POUF1, OMIM 601538)
s located on chromosome 5q35.31 and encodes a 226-amino acid
ranscription factor.4 PROP1 mutations have been ﬁrstly described
n Ames dwarf mice.5 Ames dwarf mutants carry a homozygous
utation that involves a serine-to-proline substitution of amino
cid 83 (S83P), associated with multiple hormone deﬁciencies,
amely GH, PRL, TSH and LH and FSH and with adult pituitary
ypoplasia. Since then, several Prop1 mutations that structurally
ffect the ‘paired-like’ DNA-binding domain of the Prop-1 protein
olecule have been described.1
Combined pituitary hormone deﬁciency by PROP1 mutations
s an autosomal recessive disorder, and most of the patients do
ot present any family history of the disease. Thus, each sib-
ing has 25% risk of being affected.6 Since PROP1 gene encodes
 transcription factor involved in the ontogeny, differentiation
nd function of somatotrophs, lactotrophs, gonadotrophs and thy-
otrophs, patients with PROP1 mutations show combined pituitary
ormone deﬁciency.7 They are characterized by a remarkable clin-
cal variability, including time of onset of hormonal deﬁciencies,
ypophyseal dimensions and secretion of cortisol. In a multicen-
ric study launched in Portugal to screen for mutations of the PROP1
ene in patients with combined pituitary hormone deﬁciency, the
ost frequent mutation found was c.301–302delAG, also known
s 296delGA. This 2-bp deletion in a dinucleotide repeat muta-
ional hotspot is also the most prevalent mutation described in
ther studies.6
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Legend:
Case report
We  describe a family of consanguineous parents (second-degree
cousins), composed of 7 siblings, of which 4 present combined
pituitary hormone deﬁciency and have been followed by the
department of Endocrinology (family heredogram in Fig. 1). There
was no previous family history of combined pituitary deﬁciency.
Patients’ phenotype and diagnosis
Patient #1, the older sister, aged 50-years-old, had unremark-
able neonatal period and psychomotor development. Failure to
thrive was noticed when she was  9-years-old. Afterwards, docu-
mentation of GH, TSH, FSH/LH, prolactin and cortisol deﬁciency
conﬁrmed the diagnosis of combined pituitary hormone deﬁciency.
She had initiated growth hormone therapeutic and, at adult age,
she presented a ﬁnal stature of 1.47 m and a body mass index of
32.9 kg/m2. She is currently being supplemented with levotirox-
ine 250 mcg  qd, hydrocortisone 25 mg  qd and desogestrel/ethynil
estradiol (0.15/0.02 mg).
Patient #2, female, aged 46, was also born by normal delivery, at
term, and presented an unremarkable neonatal and psychomotor
development. Growth retardation and lack of pubertal develop-
ment were noticed when she was 15-years old. Documentation
of GH, TSH, FSH/LH, prolactin and ACTH deﬁciency conﬁrmed
the diagnosis of combined pituitary hormone deﬁciency. She was
treated with adequate complete hormone replacement therapy,
acquiring an adult stature of 1.5 m (BMI of 35.97 m2). She is cur-
rently under levotiroxine 250 mcg  qd, hydrocortisone 20 mg qd and
estradiol valerate/Norgestrel (2/0.5 mg).
Patient #3, male, 45-years-old, also did not show any com-
plication during neonatal period or concerning psychomotor
development. An initial diagnosis of dwarﬁsm was performed at
age 12. Subsequently, it was detected TSH, FSH/LH and prolactin
deﬁciency, as well as cortisol deﬁciency. With adequate hormonal
supplementation, including growth hormone therapeutic, at adult
age he reached 1.68 m of stature (BMI of 30.67 kg/m2). He is medi-
cated with levothyroxine 200 mcg  qd, hydrocortisone 25 mg qd and
testosterone decanoate 4/4 weeks.
Patient #4, male, the youngest sibling, 41-years-old, was born
by normal delivery, at term, with a normal birth length. His neu-
ropsychomotor development was normal. Growth retardation was
the ﬁrst signal at 9-years old. Clinical data and standard stimulation
tests allowed the detection of TSH, FSH/LH and prolactin deﬁciency,III
1 2 3 4
Fig. 1. Family heredogram. Number 1, 2, 3 and 4 inside de boxes reprPanhypopituitarism by PROP1 mutation
esent the patients #1, #2, #3 and #4, described along the text.
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eading to the diagnosis of combined pituitary hormone deﬁciency.
e did hormone replacement therapy, including growth hormone
reatment, acquiring a ﬁnal stature at adult stage of 1.51 m (BMI of
6.18 kg/m2). Up until now, he maintains adrenal sufﬁciency and
s presently being supplemented with levothyroxine 225 mcg
nd testosterone decanoate 4/4 weeks.
ituitary morphology
Pituitary morphology by imaging study was only performed in
atients #1, 3 and 4.
Patients #3 and #4 had performed a CT scan, which revealed no
lterations. On patient #1, MRI  showed pituitary hypoplasia.
olecular genetic analysis
The genetic study was performed in the 4 brothers, amplifying
ROP1 gene by polymerase chain reaction. It has allowed the iden-
iﬁcation of a homozygous mutation in the PROP1 gene with a 2-bp
eletion (c.301–302delAG). This mutation involves a 2 bp GA or AG
eletion among three tandems GA repeats (296-GAGAGAG-302)
f exon II (Fig. 2). The change in reading frame causes a diver-
ence in amino acid sequence at codon 102, and the serine at codon
09 is changed to a stop codon (S109X). The resulted truncated gene
s inactive, which leads to the described hormone abrogation.
iscussion
Pituitary development depends on a high complex process,
nvolving a sequential expression of transcription factors, respon-
ible in the end for an adequate production of the ﬁve types
f cell populations – somatotrophs, lactotrophs, thyrotrophs,
onadotrophs, and corticotrophs.8 Thereby, any disturbances of
hese transcriptional factors can have deleterious effects on pitu-
tary development and hormonal production. Combined pituitary
ormonal deﬁciency genetically determined is due to mutations in
he PROP1 gene in nearly half of the cases.3
PROP1 expression is essential to allow Pit1-speciﬁc cells and
he gonadotropic lineage differentiation. PROP1 mutations are
haracterized by a notably high variable phenotype presentation.
H and TSH deﬁciency are frequently the ﬁrst manifestations of
isease. Usually, the ﬁrst signs, namely progressive growth fail-
re, only occur in childhood, not before 6 years of age. Perinatal
igns of hypopituitarism are rare, comparing to other genetic
orms of combined hormonal pituitary deﬁciency.9 Lactotroph
unction and hypogonadism are also different among patients with
ROP1 mutation. Prolactin production differs between patients,
lthough usually they are at lower levels than normal.10 Concerningetes Metab. 2016;11(1):41–44 43
puberty development, its onset depends on the patient; some do
not produce sufﬁcient LH and FSH to initiate puberty, whereas oth-
ers develop progressive gonadotroph failure and do not complete
puberty.11 These observations lead to the hypothesis that PROP1
gene may  play a key role in gonadotroph differentiation.12 Other
authors, taking into account experimental observations, consider
that PROP1 directly activates gonadotropin gene expression.13 In
our case report, the ﬁrst sign of disease was  growth retardation
and the two  brothers were ﬁrstly diagnosed of dwarﬁsm at the age
of 12 and 9, being the other hormonal deﬁciencies (TSH, prolactin
and FSH/LH) diagnosed later.
Adrenal insufﬁciency seems to be controversial, although there
is growing evidence that ACTH impairment is a late-onset com-
plication in patients with PROP1 mutations.14 In a retrospective
longitudinal analysis of nine patients with PROP1 mutations, all
patients developed at least partial cortisol insufﬁciency and a
progressive decline of the pituitary–adrenal axis was observed.9
Therefore, anterior pituitary function seems to be a continuum that
tends to deteriorate progressively and adrenal insufﬁciency is a per-
fect example of this condition. From this perspective, PROP1 may
also play a role in corticotroph cells differentiation and it is possi-
ble that these cells suffer progressive apoptosis with subsequently
decrease of ACTH secretion.15 The inexistence of adrenal insufﬁ-
ciency at one point does not exclude the development of inadequate
production of cortisol later. As we observed, all except one of our
patients affected by PROP1 gene mutation developed adrenal insuf-
ﬁciency, being essential to monitor the adrenal function of the
patient that has not yet been affected.
As we might conclude, the progressive disruption of all anterior
pituitary axis in patients carrying PROP1 mutations has important
clinical consequences regarding diagnosis, prognosis and manage-
ment of the patients.16 Clinicians should be aware of these defects,
monitoring hormonal status since the diagnosis, even if patients do
not present all hormonal deﬁciencies at the initial stages, as they
are at increased risk of developing them. Unfortunately, it has been
impossible to predict the time point of occurrence of these changes
up until now, which implies a strict and careful follow-up.
Pituitary size or morphologic alterations are also matter of
debate. While some patients present normal pituitary gland on
imaging studies, others have hypoplasic pituitary gland.17 One Por-
tuguese study conducted in patients with PROP1 mutations found
out that all patients had pituitary hypoplasia or empty sella except
one, who presented an enlarged sellar mass.6 One  explanation for
this is that this enlargement, generally presented in early child-
hood, will be followed by regression and involution of that tissue,
resulting in an empty sella.18 Out of the 3 patients of our case report
that were evaluated by imaging study, two had normal pituitary
gland and the last one had pituitary hypoplasia.
It is also difﬁcult to establish a concrete correlation between
genotype–phenotype among the diverse forms of presentation of
this disease and the different degree of loss function between the
reported mutations.19 As we  observed in this family, there is a
strong variability either at the age of diagnosis, the time of onset of
hormone deﬁciencies, pituitary morphology and ACTH and cortisol
status, besides the 4 patients were affected by the same mutation.
This observation emphasizes the impact of interindividual differ-
ences on clinical phenotype by PROP1 mutations. Furthermore, it
seems that these differences tend to be attenuated throughout the
years, as hormone insufﬁciency in adults seems to be similar among
the subjects.Conclusion
This case study exempliﬁes the clinical expression of com-
bined pituitary hormone deﬁciency due to PROP1 mutations. As
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e observed in this family, mutations in PROP1 gene are associated
ith a variable phenotype expression, from time of onset of hor-
onal abnormalities, hormonal status, namely cortisol sufﬁciency,
o pituitary morphologic changes. In this regards, an early diagno-
is and a careful long-term follow-up are crucial to improve overall
atients’ clinical condition, as anterior pituitary function declines
radually.
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